OAKLAND, Calif., June 5, 2015 /PRNewswire-USNewswire/ — The registered nurses of National Nurses United (NNU) are stepping up pressure on several members of Congress, urging them to vote “No” when the US House of Representatives considers Fast Track authority for the Trans-Pacific Partnership (TPP).
The ads, which begin running on local stations today in six media markets, emphasize that “right now, our government is negotiating new international trade agreements that will make lifesaving drugs much more expensive—especially ones that show promise in battling cancer, MS and Alzheimer’s disease.”
Congressional members identified as having swing votes and in whose districts the ads will run are: Rep. Steny Hoyer, Rep. Seth Moulton, Rep. Sam Farr, Rep. Beto O’Rourke, Rep. Susan Davis, and Rep. Ruben Hinojosa.
Martha Kuhl, RN, Secretary-Treasurer of NNU, who speaks in the ads, says Fast Track eliminates the ability to amend any aspect of the proposed trade deal. The TPP has been roundly criticized for, among other things, increasing the cost of prescription drugs and reducing access to lifesaving medication.
A Doctors Without Borders report says, “the US government is pushing policies in the TPP that represent the most far-reaching attempt to date to impose aggressive Intellectual Property (IP) standards in a trade agreement with developing countries— policies that further tip the balance towards strong IP regimes favoring commercial interests and away from public health.
“For pharmaceuticals and other health commodities, stronger IP regimes mean extended patent monopolies and delayed generic competition, and that translates into higher prices for people who need medicines. In developing countries, where people rarely have health insurance and must pay for medicines out of pocket, high prices keep lifesaving medicines out of reach and are often a matter of life and death.”
Joining with community, public health, labor, religious groups and others, nurses from across the country, members of National Nurses United (NNU), the largest union and association of registered nurses in the U.S., are urging these Congressmembers, to vote “No” to Fast Track international trade negotiations.
“I’ve never been so proud of the American labor movement and its leader Richard Trumka, President of the AFL-CIO, giving voice and force to working people against multinational corporations. It is an inspiring moment up against such enormous wealth, political power and false promises,” said RoseAnn DeMoro, NNU’s executive director.
“The secretive nature of Fast Track is an affront to democracy and to our national traditions of open and honest public debate,” said Jean Ross, RN, NNU Co-President, who also appears in the ads. “With so much at stake—food safety, the cost of critical medicines, limiting industrial pollution—we urge Congress to listen to our call to stop Fast Track now.”
“What’s been leaked in this secretive procedure is startling,” said Martha Kuhl, RN, NNU secretary-treasurer. “This treaty undermines food safety by lowering standards on imported foods. It undermines environmental regulation, as well, making it easier for corporations to fight bans on toxic practices. It is a disaster for the public’s health.”
National Nurses United (NNU) is the largest organization of registered nurses in the U.S., with 190,000 members nationwide.
S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD. We are especially pleased for S1 Biopharma’s Dr. Robert Pyke who fathered flibanserin at Boehringer Ingelheim before it was acquired by Sprout Pharmaceuticals. Dr. Pyke joined S1 Biopharma as Chief Medical Officer in 2012 to develop our next-generation drug for HSDD, Lorexys.
HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity that cannot be accounted for by another medical, physical, or psychiatric condition, or medication. An estimated 1 in 10 women may have HSDD at some point in their life, for which therapies like flibanserin with a 9%- 13% responder rate over placebo, and S1 Biopharma’s first in class, next-generation drug Lorexys have been developed to address.
S1 Biopharma is currently preparing for upcoming Phase IIb studies for Lorexys for the treatment of HSDD. In its recently completed Phase IIa study, Lorexys demonstrated a 76% responder rate that was 38% greater than control.